SUO 2024
Get the latest research and practical clinical applications from the 25th Annual Meeting of the Society of Urologic Oncology.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
Standard risk assessment plus genomic classification for prostate cancer surveillance helps predict disease progression.
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
Dr. Christopher Cutie shares his thoughts on the potential of TAR-200 to redefine care for BCG-unresponsive, HR NMIBC.
Dr. Christopher Cutie describes the innovative TAR-200 system and its role in providing sustained intravesical drug delivery.
Radical prostatectomy with pelvic lymph node dissection increases risks of complications like DVT and lymphatic leaks.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
Results of the phase III BOND-003 trial show groundbreaking results of cretostimogene grenadenorepvec for NMIBC.
Treatment With Investigational TAR-200 Demonstrates Promising Results With BCG-Unresponsive HR NMIBC
TAR-200 monotherapy is well tolerated and shows promising efficacy in treating HR NMIBC, according to data from SunRISe-1. 
Patient-derived organoids show promise in RCC, enabling personalized therapies and resistance insights.
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
The phase 3 trial evaluates combination mevrometostat in patients with mCRPC previously treated with abiraterone acetate.
TARA-002 shows promising efficacy, safety in the ADVANCED-2 trial for NMIBC, with high response rates across BCG exposures.
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Machine learning models can help with clinical decision making regarding renal function, according to new data.
Ferring has advanced three clinical trials assessing nadofaragene as a monotherapy and combination therapy for NMIBC.
Locoregional recurrence can result in poor prognosis, and reported cases vary widely in medical literature.
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA+ post-cystectomy.
Several posters and a late-breaking abstract will highlight data on cretostimogene grenadenorepvec for bladder cancer.
The real-world analysis of olaparib for HRRm+ CRPC showed that earlier treatment resulted in higher PFS and OS.
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.